Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Colorectal Clear all
Active, not recruiting Phase 1 Interventional

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

NCT03845166
View directory record Official record
Conditions
Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
Interventions
XL092, Atezolizumab, Avelumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 10, 2026, 11:46 PM EDT
Active, not recruiting Early Phase 1 Interventional Results available

ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension

NCT05056896
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Aspirin, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 10, 2026, 11:46 PM EDT
Completed No phase listed Observational

The Inland Northwest Colon Cancer Survivor's Study

NCT01775254
View directory record Official record
Conditions
Colon Cancer
Interventions
Not listed
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 10, 2026, 11:46 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

NCT00003594
View directory record Official record
Conditions
Colorectal Cancer
Interventions
irinotecan, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
430
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 261 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Sep 10, 2026, 11:46 PM EDT
Recruiting Phase 1 Interventional

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

NCT06462183
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Colorectal Cancer
Interventions
RGT-61159
Drug
Lead sponsor
Rgenta Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 10, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy

NCT00083720
View directory record Official record
Conditions
Colorectal Neoplasms, Metastases, Neoplasm
Interventions
cetuximab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
23
States / cities
Campbell, California • Los Angeles, California • Soquel, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Sep 10, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

NCT01931150
View directory record Official record
Conditions
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Interventions
Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 10, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening

NCT04607291
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Community Health Service, Survey Administration
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 10, 2026, 11:46 PM EDT
Recruiting Phase 2 Interventional

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

NCT05024097
View directory record Official record
Conditions
Rectal Cancer
Interventions
Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122)
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 10, 2026, 11:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

NCT01619423
View directory record Official record
Conditions
Advanced Metastatic (Stage IV) Colorectal Cancer
Interventions
PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl)
Drug
Lead sponsor
Egetis Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
La Jolla, California • Bethesda, Maryland • Chattanooga, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 10, 2026, 11:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Preventive Health Behavior in Women

NCT00723996
View directory record Official record
Conditions
Colon Cancer
Interventions
Behavioral Study in Women
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 10, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer

NCT00612586
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Enzastaurin, Placebo, Leucovorin (LV), 5-fluorouracil (5-FU), Bevacizumab (Bev)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Memphis, Tennessee • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 10, 2026, 11:46 PM EDT
Completed Phase 1 Interventional

Study of XL281 in Adults With Solid Tumors

NCT00451880
View directory record Official record
Conditions
Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma
Interventions
XL281, famotidine
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Sep 10, 2026, 11:46 PM EDT
Completed No phase listed Observational

Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

NCT04813627
View directory record Official record
Conditions
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions
Regular blood sample collection for ctDNA assessment
Procedure
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
2,079 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
California City, California • Concord, California • Greenbrae, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 10, 2026, 11:46 PM EDT
Completed Phase 2 Interventional

Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer

NCT00020917
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, fluorouracil, irinotecan hydrochloride, leucovorin calcium
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Sep 10, 2026, 11:46 PM EDT
Completed Phase 1Phase 2 Interventional

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

NCT02335918
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
Interventions
Combination of varlilumab and nivolumab
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 10, 2026, 11:46 PM EDT
Completed Not applicable Interventional

System-Wide Improvement for Transitions After Surgery: The SWIFT Post op Program

NCT02543190
View directory record Official record
Conditions
Colectomy, Colorectal Surgery, Ileostomy
Interventions
compliance surveillance and improvement strategy
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 10, 2026, 11:46 PM EDT
Terminated Not applicable Interventional Results available

SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study

NCT05010850
View directory record Official record
Conditions
Colorectal Cancer, Rectal Cancer, Rectal Tumor, Rectal/Anal
Interventions
Colovac, Stoma Creation
Device · Procedure
Lead sponsor
SafeHeal Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Worcester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 10, 2026, 11:46 PM EDT
Terminated Phase 1 Interventional

Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

NCT01126450
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
lenalidomide, cetuximab, mutation analysis, polymerase chain reaction, polymorphism analysis
Drug · Biological · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Sep 10, 2026, 11:46 PM EDT
Not listed No phase listed Observational

Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project

NCT01815879
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases
Interventions
Not listed
Lead sponsor
Andrew Kennedy
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 10, 2026, 11:46 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.

NCT04739696
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Colon Cancer, Solid Tumor, Adult
Interventions
PEPRR, Pep-Pal
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 10, 2026, 11:46 PM EDT
Terminated Phase 4 Interventional

Ischemic Conditioning (Delay Phenomenon) in Colorectal Surgery

NCT00887497
View directory record Official record
Conditions
Colon Rectal Resection
Interventions
Angioembolization
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Sep 10, 2026, 11:46 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Healthcare Decisions Post-Testing, Risk-reducing and Preventative Strategies Using LYNCH Genetic Testing Reducing, and Preventative Strategies Using LYNCH Genetic Testing

NCT03322176
View directory record Official record
Conditions
Colon Cancer, Endometrial Cancer
Interventions
Genetic testing
Other
Lead sponsor
Data Collection Analysis Business Management
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Land O' Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 10, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

NCT01037790
View directory record Official record
Conditions
Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma
Interventions
PD-0332991
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 10, 2026, 11:46 PM EDT